U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07674498) titled 'Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma' on June 11.
Brief Summary: Relapsed/refractory multiple myeloma (RRMM) predominantly affects older adults, who exhibit marked heterogeneity in treatment outcomes despite receiving the same therapies. Clinical frailty scores, such as the International Myeloma Working Group (IMWG) Frailty Index, predict survival and treatment tolerance but provide limited information on immune competence, a key determinant of response to T-cell-based immunotherapies.
The PRIME study is a prospective, multicenter, non-interventional exploratory study designed to evaluate t...